Resilience and Harvard University launch R&D alliance for biologics
The new alliance will focus on the development and manufacturing of complex medicines including biologics, vaccines, nucleic acids and cell and gene therapies; as well as looking to launch companies to advance the manufacture of such medicines.
Source: biopharma-reporter.com